We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
AbCellera Biologics Inc.
Health Care · Biotechnology
Antibody-discovery platform - single-cell microfluidics + deep-sequencing + ML to identify and optimize antibody candidates rapidly. Canadian-listed (CAD reporting). Pipeline transition underway: from pure platform-royalty model toward direct internal candidates.
Lead ABCL635 on track for Phase 2 top-line Q3 2026. Cash position CAD 531M + CAD 124M in government funding available.
No major news in the last 7 days for ABCL - only listicles and opinion pieces, which we filter out by default. See everything anyway.
No key levels recorded for this ticker.